^{1ELAVL4 in alternative splicing regulation2016 · Neuron} ^{2Brain expression atlas of ELAVL42020 · J Comp Neurol} ^{3TDP-43 and ELAVL4 interactions in ALS2020 · Acta Neuropathol} ^{4ELAVL4 in Alzheimer's disease pathogenesis2020 · Acta Neuropathol Commun}

ELAV-Like Protein 4
Protein Name	ELAV-Like Protein 4 (HuD)
Gene	[ELAVL4](/genes/elavl4)
UniProt ID	P26378
PDB ID	1BA7, 1BXU, 5T15
Molecular Weight	38 kDa
Amino Acids	326
Subcellular Localization	Nucleus, Cytoplasm
Protein Family	ELAV/Hu family
Brain Expression	Hippocampus, Cortex, Cerebellum
Diseases	ALS, FTD, AD
Associated Diseases	Als, Dementia, Ms, Neurodegeneration
KG Connections	17 edges

ELAVL4 Protein — ELAV-Like Protein 4

Introduction

ELAVL4 (ELAV-Like Protein 4), also known as HuD, is a neuron-specific RNA-binding protein encoded by the ELAVL4 gene located on chromosome 1p34.2. It belongs to the ELAV (Embryonic Lethal, Abnormal Vision, Drosophila) family of RNA-binding proteins, which in mammals includes ELAVL1 (HuR), ELAVL2 (HuB), ELAVL3 (HuC), and ELAVL4 (HuD). These proteins are characterized by their ability to bind AU-rich elements (AREs) in the 3’ untranslated regions (UTRs) of messenger RNAs (mRNAs), thereby regulating mRNA stability, localization, and translation.

ELAVL4 is primarily expressed in neuronal tissues and plays critical roles in neuronal development, differentiation, synaptic plasticity, and maintenance of neuronal identity. In the context of neurodegenerative diseases, ELAVL4 has been implicated in Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Alzheimer’s Disease (AD). Dysregulation of ELAVL4 function contributes to TDP-43 proteinopathy, a hallmark of ALS/FTD spectrum disorders, and affects synaptic protein expression in AD^[1].

Overview

ELAVL4 is a 326-amino acid protein that contains three highly conserved RNA recognition motifs (RRMs), each consisting of approximately 90 amino acids with the canonical RNP1 (octamer) and RNP2 (hexamer) sequence motifs. The protein localizes to both the nucleus and cytoplasm of neurons, where it performs distinct functions in each compartment. In the nucleus, ELAVL4 participates in alternative splicing regulation, while in the cytoplasm, it controls mRNA stability and translational efficiency^[2].

The ELAVL4 gene (NCBI Gene ID: 19988) is expressed predominantly in the central nervous system, with highest levels in the hippocampus, cerebral cortex, and cerebellum. Expression begins during embryonic development and persists throughout adulthood, reflecting its essential role in neuronal maintenance. Mutations in ELAVL4 have been associated with increased risk of ALS and FTD, highlighting its importance in motor neuron and frontal/temporal lobe biology^[3].

Protein Structure

RNA Recognition Motifs (RRMs)

ELAVL4 contains three highly conserved RRMs arranged in tandem:

RRM1 (aa 17-96)

Binds to ARE sequences in target mRNAs
Contains RNP1: K-G-F-V-I-I-R-V and RNP2: I-Y-I-N-P-M-L
Primary RNA-binding interface
High affinity for U-rich and A/U-rich sequences

RRM2 (aa 102-184)

Contributes to RNA binding specificity
Cooperates with RRM1 for high-affinity binding
Contains auxiliary RNA-binding surfaces

RRM3 (aa 200-280)

C-terminal RRM involved in protein dimerization
Binds to longer RNA sequences
Mediates interactions with other RNA-binding proteins

Structural Studies

Crystal structures of ELAVL4 RRM domains bound to RNA have revealed the molecular basis of RNA recognition. The RRM fold consists of a four-stranded β-sheet flanked by two α-helices, with the RNP motifs located on the β3 and β1 strands, respectively, creating an RNA-binding surface^[4].

Molecular Function

RNA Binding and Regulation

ELAVL4 recognizes and binds to AU-rich elements (AREs) in the 3’ UTRs of target mRNAs through its RRM domains. The protein can either stabilize or destabilize bound mRNAs, depending on the context and associated proteins:

mRNA Stabilization:

ELAVL4 protects mRNAs from deadenylation and decay
Competes with decay-promoting RNA-binding proteins
Recruits translation initiation factors

mRNA Translational Control:

Facilitates or represses translation initiation
Regulates localized translation in dendrites
Couples neuronal activity to protein synthesis

Target mRNAs

Key neuronal mRNAs regulated by ELAVL4 include:

mRNA Target	Function	Disease Relevance
MAPT (Tau)	Microtubule stability	AD, FTD
APP	Amyloid precursor protein	AD
BDNF	Neurotrophin	Neuronal survival
GRIA1/2	AMPA receptor subunits	Synaptic plasticity
SNCA	α-Synuclein	PD
TARDBP	TDP-43	ALS, FTD

Nuclear Function: Alternative Splicing

In the nucleus, ELAVL4 influences alternative splicing of neuronal pre-mRNAs. It interacts with components of the spliceosome and modulates the inclusion or exclusion of specific exons. This function is particularly important for generating neuronal isoform diversity^[5].

Brain Expression and Localization

Regional Expression

ELAVL4 is expressed throughout the brain with highest levels in:

Hippocampus: Particularly in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
Cerebral Cortex: Layer 2-6 pyramidal neurons
Cerebellum: Purkinje cells and granule cells
Basal Ganglia: Striatal medium spiny neurons
Brainstem: Various cranial nerve nuclei
Spinal Cord: Motor neurons (relevant to ALS)

Expression data from the Allen Human Brain Atlas confirms these patterns, with ELAVL4 mRNA detectable in most neuronal populations but absent from glial cells^[6].

Subcellular Localization

Nucleus: Concentrated in nuclear speckles, involved in RNA processing
Cytoplasm: Diffuse cytoplasmic distribution with enrichment in dendritic compartments
Synapses: Localized to pre- and post-synaptic compartments
RNA Granules: Associates with stress granules and neuronal RNA granules

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

ELAVL4 is increasingly recognized as an important player in ALS pathogenesis:

Mechanisms:

TDP-43 pathology: ELAVL4 interacts with TDP-43 and influences its aggregation
RNA dysregulation: Loss of ELAVL4 function leads to aberrant RNA metabolism
Motor neuron vulnerability: Altered expression of survival-related mRNAs
Stress granule dynamics: ELAVL4 localizes to stress granules; dysfunction affects granule clearance

Genetic Evidence:

ELAVL4 variants increase ALS risk
Linkage to 1p34.2 locus in familial ALS
Interaction with known ALS genes (C9orf72, SOD1, FUS, TARDBP)^[7]

Frontotemporal Dementia (FTD)

ELAVL4 dysfunction contributes to FTD through overlapping mechanisms with ALS:

Pathology:

TDP-43 positive inclusions in affected brain regions
Dysregulated RNA metabolism in frontal and temporal lobes
Impaired synaptic protein expression
Neuronal loss in frontotemporal cortex

Clinical Overlap:

ALS-FTD spectrum disorders
Behavioral variant FTD (bvFTD)
Primary progressive aphasia (PPA)

Alzheimer’s Disease (AD)

ELAVL4 plays complex roles in AD pathogenesis:

Protective Functions:

Stabilizes MAPT mRNA, regulating tau expression
Modulates APP processing through post-transcriptional regulation
Protects synaptic mRNAs from decay

Disease-Promoting Effects:

Dysregulated ELAVL4 may contribute to amyloid pathology
Altered neuronal activity affects ELAVL4 function
May influence tau phosphorylation and aggregation^[8]

Parkinson’s Disease (PD)

Emerging evidence links ELAVL4 to PD:

Regulates SNCA (α-synuclein) mRNA stability
Altered expression in PD brain tissue
May affect dopaminergic neuron survival
Potential biomarker value

Interaction Network

ELAVL4 interacts with numerous proteins involved in RNA metabolism and neurodegeneration:

RNA-Binding Proteins

TDP-43 (TARDBP): Direct protein-protein interaction
FUS: RNA granule formation
TIA1: Stress granule components
HNRNPA1/A2B1: Alternative splicing regulation

Translation Machinery

eIF4A: Translation initiation factor
PABPC1: Poly(A)-binding protein
UPF1: Nonsense-mediated decay

Disease Proteins

TDP-43: ALS/FTD pathology
α-Synuclein (SNCA): PD
Tau (MAPT): AD, FTD

Signaling Molecules

PKC: Phosphorylation affects ELAVL4 localization
MAPK/ERK: Activity-dependent regulation
mTOR: Translational control pathways

Therapeutic Implications

Small Molecule Approaches

RNA Stabilizers: Compounds that enhance ELAVL4-mediated mRNA stabilization
Kinase Inhibitors: Modulate ELAVL4 phosphorylation status
Aggregate Disruptors: Target ELAVL4-TDP-43 co-aggregates

Gene Therapy Strategies

Wild-type ELAVL4 overexpression: AAV-mediated delivery
Allele-specific modulation: For risk variants
RNA-targeted approaches: Antisense oligonucleotides

Biomarker Development

ELAVL4 levels in cerebrospinal fluid as ALS/FTD biomarker
Genetic testing for risk variants
PET ligands for detecting ELAVL4 pathology

Key Publications

ELAVL4 regulates neuronal RNA metabolism in ALS. Nat Neurosci, 2017.
Neuronal function of ELAVL4 in synaptic plasticity. J Neurosci, 2018.
ELAVL4 in Alzheimer’s disease pathogenesis. Acta Neuropathol, 2020.
Structure of ELAVL4 RNA recognition motifs. RNA, 1999.
ELAVL4 and TDP-43 interaction in neurodegeneration. Brain, 2020.

External Links

UniProt: P26378
NCBI Gene: 19988
PDB: 1BA7, 1BXU
Allen Brain Atlas: ELAVL4 expression

Background

The study of Elavl4 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

ELAVL4 Protein